1. Home
  2. ICFI vs MLYS Comparison

ICFI vs MLYS Comparison

Compare ICFI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICF International Inc.

ICFI

ICF International Inc.

N/A

Current Price

$98.47

Market Cap

1.7B

ML Signal

N/A

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$15.91

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ICFI
MLYS
Founded
1969
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
2006
2023

Fundamental Metrics

Financial Performance
Metric
ICFI
MLYS
Price
$98.47
$15.91
Analyst Decision
Buy
Strong Buy
Analyst Count
5
11
Target Price
★ $107.25
$45.22
AVG Volume (30 Days)
127.3K
★ 1.5M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
★ 0.59%
N/A
EPS Growth
N/A
★ 37.43
EPS
★ 2.61
N/A
Revenue
★ $1,229,162,000.00
N/A
Revenue This Year
$1.68
N/A
Revenue Next Year
$5.88
N/A
P/E Ratio
$36.45
★ N/A
Revenue Growth
★ 3.72
N/A
52 Week Low
$58.83
$18.12
52 Week High
$98.03
$47.65

Technical Indicators

Market Signals
Indicator
ICFI
MLYS
Relative Strength Index (RSI) 74.93 24.51
Support Level $74.27 N/A
Resistance Level N/A $31.19
Average True Range (ATR) 2.65 1.35
MACD 0.74 -0.23
Stochastic Oscillator 93.77 4.38

Price Performance

Historical Comparison
ICFI
MLYS

About ICFI ICF International Inc.

ICF International Inc provides professional services and technology-based solutions, including management, technology and policy consulting and implementation services, to government and commercial clients in the U.S. and internationally. Its government clients include U.S. federal agencies, state and local governments and international governments, as well as commercial clients inside and outside the U.S. It supports clients in Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs; and Security and Other Civilian and Commercial markets. The company delivers services across the life cycle of a policy, program or project through Advisory Services, Program Implementation, Analytics Services, Digital Services and Engagement Services.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: